AAC97486.1
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
46,484 Da
NCBI Official Full Name
calcium-independent phospholipase A2
NCBI Official Synonym Full Names
phospholipase A2, group VI (cytosolic, calcium-independent)
NCBI Official Synonym Symbols
GVI; PLA2; INAD1; NBIA2; iPLA2; NBIA2A; NBIA2B; PARK14; PNPLA9; CaI-PLA2; IPLA2-VIA; iPLA2beta [Similar Products]
NCBI Protein Information
85/88 kDa calcium-independent phospholipase A2; GVI PLA2; iPLA2-beta; group VI phospholipase A2; 85 kDa calcium-independent phospholipase A2; patatin-like phospholipase domain containing 9; cytosolic, calcium-independent phospholipase A2; neurodegeneration with brain iron accumulation 2; patatin-like phospholipase domain-containing protein 9; intracellular membrane-associated calcium-independent phospholipase A2 beta
UniProt Protein Name
85/88 kDa calcium-independent phospholipase A2
UniProt Synonym Protein Names
Group VI phospholipase A2; GVI PLA2; Intracellular membrane-associated calcium-independent phospholipase A2 beta; iPLA2-beta; Patatin-like phospholipase domain-containing protein 9; PNPLA9
UniProt Synonym Gene Names
UniProt Entry Name
PLPL9_HUMAN
NCBI Summary for PNPLA8
The protein encoded by this gene is an A2 phospholipase, a class of enzyme that catalyzes the release of fatty acids from phospholipids. The encoded protein may play a role in phospholipid remodelling, arachidonic acid release, leukotriene and prostaglandin synthesis, fas-mediated apoptosis, and transmembrane ion flux in glucose-stimulated B-cells. Several transcript variants encoding multiple isoforms have been described, but the full-length nature of only three of them have been determined to date. [provided by RefSeq, Dec 2010]
UniProt Comments for PNPLA8
PLA2G6: Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells. Has a role in cardiolipin (CL) deacylation. Required for both speed and directionality of monocyte MCP1/CCL2-induced chemotaxis through regulation of F- actin polymerization at the pseudopods. Defects in PLA2G6 are the cause of neurodegeneration with brain iron accumulation type 2B (NBIA2B). A neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. It is characterized by progressive extrapyramidal dysfunction leading to rigidity, dystonia, dysarthria and sensorimotor impairment. Defects in PLA2G6 are the cause of neurodegeneration with brain iron accumulation type 2A (NBIA2A); also known as Seitelberger disease. NBIA2A is a neurodegenerative disease characterized by pathologic axonal swelling and spheroid bodies in the central nervous system. Onset is within the first 2 years of life with death by age 10 years. Defects in PLA2G6 are the cause of Parkinson disease type 14 (PARK14). An adult-onset progressive neurodegenerative disorder characterized by parkinsonism, dystonia, severe cognitive decline, cerebral and cerebellar atrophy and absent iron in the basal ganglia on magnetic resonance imaging. 4 isoforms of the human protein are produced by alternative splicing.
Protein type: Lipid Metabolism - ether lipid; Lipid Metabolism - arachidonic acid; Lipid Metabolism - linoleic acid; Lipid Metabolism - glycerophospholipid; Phospholipase; Lipid Metabolism - alpha-linolenic acid; EC 3.1.1.4
Chromosomal Location of Human Ortholog: 22q13.1
Cellular Component: mitochondrion; membrane; cytoplasm; microtubule organizing center; cytosol
Molecular Function: phospholipase A2 activity; calmodulin binding; ATP-dependent protein binding; calcium-independent phospholipase A2 activity
Biological Process: urinary bladder smooth muscle contraction; cardiolipin biosynthetic process; maternal process involved in pregnancy; glycerophospholipid biosynthetic process; negative regulation of synaptic transmission, glutamatergic; positive regulation of vasodilation; chemotaxis; memory; elevation of cytosolic calcium ion concentration; phospholipid metabolic process; innate immune response; positive regulation of protein amino acid phosphorylation; lipid catabolic process; positive regulation of exocytosis
Disease: Parkinson Disease 14, Autosomal Recessive; Neurodegeneration With Brain Iron Accumulation 2b; Neurodegeneration With Brain Iron Accumulation 2a
Research Articles on PNPLA8
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with PNPLA8 elisa kit
Pathways associated with PNPLA8 elisa kit
Diseases associated with PNPLA8 elisa kit
Organs/Tissues associated with PNPLA8 elisa kit
|